Change of voltage‐gated sodium channel repertoire in skeletal muscle of a MuSK myasthenia gravis mouse model

Muscle‐specific kinase myasthenia gravis (MuSK MG) is caused by autoantibodies against MuSK in the neuromuscular junction (NMJ). MuSK MG patients have fluctuating, fatigable skeletal muscle weakness, in particular of bulbar muscles. Severity differs greatly between patients, in spite of comparable a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European journal of neuroscience 2024-06, Vol.59 (12), p.3292-3308
Hauptverfasser: Butenko, Olena, Jensen, Stine Marie, Fillié‐Grijpma, Yvonne E., Verpalen, Robyn, Verschuuren, Jan J., Maarel, Silvère M., Huijbers, Maartje G., Plomp, Jaap J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3308
container_issue 12
container_start_page 3292
container_title The European journal of neuroscience
container_volume 59
creator Butenko, Olena
Jensen, Stine Marie
Fillié‐Grijpma, Yvonne E.
Verpalen, Robyn
Verschuuren, Jan J.
Maarel, Silvère M.
Huijbers, Maartje G.
Plomp, Jaap J.
description Muscle‐specific kinase myasthenia gravis (MuSK MG) is caused by autoantibodies against MuSK in the neuromuscular junction (NMJ). MuSK MG patients have fluctuating, fatigable skeletal muscle weakness, in particular of bulbar muscles. Severity differs greatly between patients, in spite of comparable autoantibody levels. One explanation for inter‐patient and inter‐muscle variability in sensitivity might be variations in compensatory muscle responses. Previously, we developed a passive transfer mouse model for MuSK MG. In preliminary ex vivo experiments, we observed that muscle contraction of some mice, in particular those with milder myasthenia, had become partially insensitive to inhibition by μ‐Conotoxin‐GIIIB, a blocker of skeletal muscle NaV1.4 voltage‐gated sodium channels. We hypothesised that changes in NaV channel expression profile, possibly co‐expression of (μ‐Conotoxin‐GIIIB insensitive) NaV1.5 type channels, might lower the muscle fibre's firing threshold and facilitate neuromuscular synaptic transmission. To test this hypothesis, we here performed passive transfer in immuno‐compromised mice, using ‘high’, ‘intermediate’ and ‘low’ dosing regimens of purified MuSK MG patient IgG4. We compared myasthenia levels, μ‐Conotoxin‐GIIIB resistance and muscle fibre action potential characteristics and firing thresholds. High‐ and intermediate‐dosed mice showed clear, progressive myasthenia, not seen in low‐dosed animals. However, diaphragm NMJ electrophysiology demonstrated almost equal myasthenic severities amongst all regimens. Nonetheless, low‐dosed mouse diaphragms showed a much higher degree of μ‐Conotoxin‐GIIIB resistance. This was not explained by upregulation of Scn5a (the NaV1.5 gene), lowered muscle fibre firing thresholds or histologically detectable upregulated NaV1.5 channels. It remains to be established which factors are responsible for the observed μ‐Conotoxin‐GIIIB insensitivity and whether the NaV repertoire change is compensatory beneficial or a bystander effect. Nerve stimulation‐evoked contraction of muscles from mild MuSK myasthenia gravis mice (injected with low doses patient IgG4) appeared partly insensitive to μ‑Conotoxin‐GIIIB. This blocker of NaV1.4 voltage‐gated sodium channels normally completely eliminates muscle contraction. We studied neuromuscular transmission and possible compensatory expression of NaV1.5 (cardiac‐type) channels but showed this was not the case. Which other Na channel types or related factors are involved r
doi_str_mv 10.1111/ejn.16347
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3045116135</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3045116135</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3487-c9d8bddd34b71b0767e79f86dd0f68f4e373459f9bac46aa50c48b68413cb8543</originalsourceid><addsrcrecordid>eNp10c1O3DAUBWCragXDwKIvUFliA4uALf9miUYUaKd0UZDYRY59k8nUSaZ2Apodj9Bn7JPUJdMukOqFvfl8dHUPQu8pOaPpnMO6O6OScfUGzSiXJMuF1G_RjOSCZZrKh310EOOaEKIlF3ton2kpCCN6hrrFynQ14L7Cj70fTA2_nn_WZgCHY--ascU2gQ48DrCBMPRNANx0OH4HD4PxuB2j9S__Df4yfvuM262Jwwq6xuA6mMcm4rYfI6TbgT9E7yrjIxzt3jm6_3h5t7jOll-vbhYXy8wyrlVmc6dL5xzjpaIlUVKByistnSOV1BUHphgXeZWXxnJpjCCW61JqTpktteBsjk6m3E3of4wQh6JtogXvTQdpmoIRLiiVlIlEj1_RdT-GLk2XlFRKSKJJUqeTsqGPMUBVbELTmrAtKCn-lFCkEoqXEpL9sEscyxbcP_l36wmcT-Cp8bD9f1Jx-el2ivwNvViR_w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3067756080</pqid></control><display><type>article</type><title>Change of voltage‐gated sodium channel repertoire in skeletal muscle of a MuSK myasthenia gravis mouse model</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Butenko, Olena ; Jensen, Stine Marie ; Fillié‐Grijpma, Yvonne E. ; Verpalen, Robyn ; Verschuuren, Jan J. ; Maarel, Silvère M. ; Huijbers, Maartje G. ; Plomp, Jaap J.</creator><creatorcontrib>Butenko, Olena ; Jensen, Stine Marie ; Fillié‐Grijpma, Yvonne E. ; Verpalen, Robyn ; Verschuuren, Jan J. ; Maarel, Silvère M. ; Huijbers, Maartje G. ; Plomp, Jaap J.</creatorcontrib><description>Muscle‐specific kinase myasthenia gravis (MuSK MG) is caused by autoantibodies against MuSK in the neuromuscular junction (NMJ). MuSK MG patients have fluctuating, fatigable skeletal muscle weakness, in particular of bulbar muscles. Severity differs greatly between patients, in spite of comparable autoantibody levels. One explanation for inter‐patient and inter‐muscle variability in sensitivity might be variations in compensatory muscle responses. Previously, we developed a passive transfer mouse model for MuSK MG. In preliminary ex vivo experiments, we observed that muscle contraction of some mice, in particular those with milder myasthenia, had become partially insensitive to inhibition by μ‐Conotoxin‐GIIIB, a blocker of skeletal muscle NaV1.4 voltage‐gated sodium channels. We hypothesised that changes in NaV channel expression profile, possibly co‐expression of (μ‐Conotoxin‐GIIIB insensitive) NaV1.5 type channels, might lower the muscle fibre's firing threshold and facilitate neuromuscular synaptic transmission. To test this hypothesis, we here performed passive transfer in immuno‐compromised mice, using ‘high’, ‘intermediate’ and ‘low’ dosing regimens of purified MuSK MG patient IgG4. We compared myasthenia levels, μ‐Conotoxin‐GIIIB resistance and muscle fibre action potential characteristics and firing thresholds. High‐ and intermediate‐dosed mice showed clear, progressive myasthenia, not seen in low‐dosed animals. However, diaphragm NMJ electrophysiology demonstrated almost equal myasthenic severities amongst all regimens. Nonetheless, low‐dosed mouse diaphragms showed a much higher degree of μ‐Conotoxin‐GIIIB resistance. This was not explained by upregulation of Scn5a (the NaV1.5 gene), lowered muscle fibre firing thresholds or histologically detectable upregulated NaV1.5 channels. It remains to be established which factors are responsible for the observed μ‐Conotoxin‐GIIIB insensitivity and whether the NaV repertoire change is compensatory beneficial or a bystander effect. Nerve stimulation‐evoked contraction of muscles from mild MuSK myasthenia gravis mice (injected with low doses patient IgG4) appeared partly insensitive to μ‑Conotoxin‐GIIIB. This blocker of NaV1.4 voltage‐gated sodium channels normally completely eliminates muscle contraction. We studied neuromuscular transmission and possible compensatory expression of NaV1.5 (cardiac‐type) channels but showed this was not the case. Which other Na channel types or related factors are involved remains to be seen.</description><identifier>ISSN: 0953-816X</identifier><identifier>EISSN: 1460-9568</identifier><identifier>DOI: 10.1111/ejn.16347</identifier><identifier>PMID: 38650308</identifier><language>eng</language><publisher>France: Wiley Subscription Services, Inc</publisher><subject>Action potential ; Animals ; Autoantibodies ; Conotoxins - pharmacology ; Diaphragm ; Disease Models, Animal ; Electrophysiology ; Female ; homeostasis ; Humans ; Immunization, Passive ; Immunoglobulin G ; Kinases ; Male ; Mice ; Muscle contraction ; Muscle, Skeletal - drug effects ; Muscle, Skeletal - metabolism ; Musculoskeletal system ; MuSK ; Myasthenia gravis ; Myasthenia Gravis - immunology ; Myasthenia Gravis - metabolism ; Myasthenia Gravis - physiopathology ; NaV channels ; neuromuscular junction ; Neuromuscular Junction - drug effects ; Neuromuscular Junction - metabolism ; Neuromuscular junctions ; passive transfer ; Receptor Protein-Tyrosine Kinases - metabolism ; Receptors, Cholinergic - immunology ; Receptors, Cholinergic - metabolism ; Skeletal muscle ; Sodium channels (voltage-gated) ; Synaptic transmission ; Voltage-Gated Sodium Channels - metabolism</subject><ispartof>The European journal of neuroscience, 2024-06, Vol.59 (12), p.3292-3308</ispartof><rights>2024 The Authors. published by Federation of European Neuroscience Societies and John Wiley &amp; Sons Ltd.</rights><rights>2024 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies and John Wiley &amp; Sons Ltd.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3487-c9d8bddd34b71b0767e79f86dd0f68f4e373459f9bac46aa50c48b68413cb8543</cites><orcidid>0000-0002-8427-9090 ; 0009-0008-1568-5942 ; 0000-0003-2538-180X ; 0000-0003-2959-559X ; 0000-0002-6082-5042</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejn.16347$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejn.16347$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38650308$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Butenko, Olena</creatorcontrib><creatorcontrib>Jensen, Stine Marie</creatorcontrib><creatorcontrib>Fillié‐Grijpma, Yvonne E.</creatorcontrib><creatorcontrib>Verpalen, Robyn</creatorcontrib><creatorcontrib>Verschuuren, Jan J.</creatorcontrib><creatorcontrib>Maarel, Silvère M.</creatorcontrib><creatorcontrib>Huijbers, Maartje G.</creatorcontrib><creatorcontrib>Plomp, Jaap J.</creatorcontrib><title>Change of voltage‐gated sodium channel repertoire in skeletal muscle of a MuSK myasthenia gravis mouse model</title><title>The European journal of neuroscience</title><addtitle>Eur J Neurosci</addtitle><description>Muscle‐specific kinase myasthenia gravis (MuSK MG) is caused by autoantibodies against MuSK in the neuromuscular junction (NMJ). MuSK MG patients have fluctuating, fatigable skeletal muscle weakness, in particular of bulbar muscles. Severity differs greatly between patients, in spite of comparable autoantibody levels. One explanation for inter‐patient and inter‐muscle variability in sensitivity might be variations in compensatory muscle responses. Previously, we developed a passive transfer mouse model for MuSK MG. In preliminary ex vivo experiments, we observed that muscle contraction of some mice, in particular those with milder myasthenia, had become partially insensitive to inhibition by μ‐Conotoxin‐GIIIB, a blocker of skeletal muscle NaV1.4 voltage‐gated sodium channels. We hypothesised that changes in NaV channel expression profile, possibly co‐expression of (μ‐Conotoxin‐GIIIB insensitive) NaV1.5 type channels, might lower the muscle fibre's firing threshold and facilitate neuromuscular synaptic transmission. To test this hypothesis, we here performed passive transfer in immuno‐compromised mice, using ‘high’, ‘intermediate’ and ‘low’ dosing regimens of purified MuSK MG patient IgG4. We compared myasthenia levels, μ‐Conotoxin‐GIIIB resistance and muscle fibre action potential characteristics and firing thresholds. High‐ and intermediate‐dosed mice showed clear, progressive myasthenia, not seen in low‐dosed animals. However, diaphragm NMJ electrophysiology demonstrated almost equal myasthenic severities amongst all regimens. Nonetheless, low‐dosed mouse diaphragms showed a much higher degree of μ‐Conotoxin‐GIIIB resistance. This was not explained by upregulation of Scn5a (the NaV1.5 gene), lowered muscle fibre firing thresholds or histologically detectable upregulated NaV1.5 channels. It remains to be established which factors are responsible for the observed μ‐Conotoxin‐GIIIB insensitivity and whether the NaV repertoire change is compensatory beneficial or a bystander effect. Nerve stimulation‐evoked contraction of muscles from mild MuSK myasthenia gravis mice (injected with low doses patient IgG4) appeared partly insensitive to μ‑Conotoxin‐GIIIB. This blocker of NaV1.4 voltage‐gated sodium channels normally completely eliminates muscle contraction. We studied neuromuscular transmission and possible compensatory expression of NaV1.5 (cardiac‐type) channels but showed this was not the case. Which other Na channel types or related factors are involved remains to be seen.</description><subject>Action potential</subject><subject>Animals</subject><subject>Autoantibodies</subject><subject>Conotoxins - pharmacology</subject><subject>Diaphragm</subject><subject>Disease Models, Animal</subject><subject>Electrophysiology</subject><subject>Female</subject><subject>homeostasis</subject><subject>Humans</subject><subject>Immunization, Passive</subject><subject>Immunoglobulin G</subject><subject>Kinases</subject><subject>Male</subject><subject>Mice</subject><subject>Muscle contraction</subject><subject>Muscle, Skeletal - drug effects</subject><subject>Muscle, Skeletal - metabolism</subject><subject>Musculoskeletal system</subject><subject>MuSK</subject><subject>Myasthenia gravis</subject><subject>Myasthenia Gravis - immunology</subject><subject>Myasthenia Gravis - metabolism</subject><subject>Myasthenia Gravis - physiopathology</subject><subject>NaV channels</subject><subject>neuromuscular junction</subject><subject>Neuromuscular Junction - drug effects</subject><subject>Neuromuscular Junction - metabolism</subject><subject>Neuromuscular junctions</subject><subject>passive transfer</subject><subject>Receptor Protein-Tyrosine Kinases - metabolism</subject><subject>Receptors, Cholinergic - immunology</subject><subject>Receptors, Cholinergic - metabolism</subject><subject>Skeletal muscle</subject><subject>Sodium channels (voltage-gated)</subject><subject>Synaptic transmission</subject><subject>Voltage-Gated Sodium Channels - metabolism</subject><issn>0953-816X</issn><issn>1460-9568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp10c1O3DAUBWCragXDwKIvUFliA4uALf9miUYUaKd0UZDYRY59k8nUSaZ2Apodj9Bn7JPUJdMukOqFvfl8dHUPQu8pOaPpnMO6O6OScfUGzSiXJMuF1G_RjOSCZZrKh310EOOaEKIlF3ton2kpCCN6hrrFynQ14L7Cj70fTA2_nn_WZgCHY--ascU2gQ48DrCBMPRNANx0OH4HD4PxuB2j9S__Df4yfvuM262Jwwq6xuA6mMcm4rYfI6TbgT9E7yrjIxzt3jm6_3h5t7jOll-vbhYXy8wyrlVmc6dL5xzjpaIlUVKByistnSOV1BUHphgXeZWXxnJpjCCW61JqTpktteBsjk6m3E3of4wQh6JtogXvTQdpmoIRLiiVlIlEj1_RdT-GLk2XlFRKSKJJUqeTsqGPMUBVbELTmrAtKCn-lFCkEoqXEpL9sEscyxbcP_l36wmcT-Cp8bD9f1Jx-el2ivwNvViR_w</recordid><startdate>202406</startdate><enddate>202406</enddate><creator>Butenko, Olena</creator><creator>Jensen, Stine Marie</creator><creator>Fillié‐Grijpma, Yvonne E.</creator><creator>Verpalen, Robyn</creator><creator>Verschuuren, Jan J.</creator><creator>Maarel, Silvère M.</creator><creator>Huijbers, Maartje G.</creator><creator>Plomp, Jaap J.</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8427-9090</orcidid><orcidid>https://orcid.org/0009-0008-1568-5942</orcidid><orcidid>https://orcid.org/0000-0003-2538-180X</orcidid><orcidid>https://orcid.org/0000-0003-2959-559X</orcidid><orcidid>https://orcid.org/0000-0002-6082-5042</orcidid></search><sort><creationdate>202406</creationdate><title>Change of voltage‐gated sodium channel repertoire in skeletal muscle of a MuSK myasthenia gravis mouse model</title><author>Butenko, Olena ; Jensen, Stine Marie ; Fillié‐Grijpma, Yvonne E. ; Verpalen, Robyn ; Verschuuren, Jan J. ; Maarel, Silvère M. ; Huijbers, Maartje G. ; Plomp, Jaap J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3487-c9d8bddd34b71b0767e79f86dd0f68f4e373459f9bac46aa50c48b68413cb8543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Action potential</topic><topic>Animals</topic><topic>Autoantibodies</topic><topic>Conotoxins - pharmacology</topic><topic>Diaphragm</topic><topic>Disease Models, Animal</topic><topic>Electrophysiology</topic><topic>Female</topic><topic>homeostasis</topic><topic>Humans</topic><topic>Immunization, Passive</topic><topic>Immunoglobulin G</topic><topic>Kinases</topic><topic>Male</topic><topic>Mice</topic><topic>Muscle contraction</topic><topic>Muscle, Skeletal - drug effects</topic><topic>Muscle, Skeletal - metabolism</topic><topic>Musculoskeletal system</topic><topic>MuSK</topic><topic>Myasthenia gravis</topic><topic>Myasthenia Gravis - immunology</topic><topic>Myasthenia Gravis - metabolism</topic><topic>Myasthenia Gravis - physiopathology</topic><topic>NaV channels</topic><topic>neuromuscular junction</topic><topic>Neuromuscular Junction - drug effects</topic><topic>Neuromuscular Junction - metabolism</topic><topic>Neuromuscular junctions</topic><topic>passive transfer</topic><topic>Receptor Protein-Tyrosine Kinases - metabolism</topic><topic>Receptors, Cholinergic - immunology</topic><topic>Receptors, Cholinergic - metabolism</topic><topic>Skeletal muscle</topic><topic>Sodium channels (voltage-gated)</topic><topic>Synaptic transmission</topic><topic>Voltage-Gated Sodium Channels - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Butenko, Olena</creatorcontrib><creatorcontrib>Jensen, Stine Marie</creatorcontrib><creatorcontrib>Fillié‐Grijpma, Yvonne E.</creatorcontrib><creatorcontrib>Verpalen, Robyn</creatorcontrib><creatorcontrib>Verschuuren, Jan J.</creatorcontrib><creatorcontrib>Maarel, Silvère M.</creatorcontrib><creatorcontrib>Huijbers, Maartje G.</creatorcontrib><creatorcontrib>Plomp, Jaap J.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The European journal of neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Butenko, Olena</au><au>Jensen, Stine Marie</au><au>Fillié‐Grijpma, Yvonne E.</au><au>Verpalen, Robyn</au><au>Verschuuren, Jan J.</au><au>Maarel, Silvère M.</au><au>Huijbers, Maartje G.</au><au>Plomp, Jaap J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Change of voltage‐gated sodium channel repertoire in skeletal muscle of a MuSK myasthenia gravis mouse model</atitle><jtitle>The European journal of neuroscience</jtitle><addtitle>Eur J Neurosci</addtitle><date>2024-06</date><risdate>2024</risdate><volume>59</volume><issue>12</issue><spage>3292</spage><epage>3308</epage><pages>3292-3308</pages><issn>0953-816X</issn><eissn>1460-9568</eissn><abstract>Muscle‐specific kinase myasthenia gravis (MuSK MG) is caused by autoantibodies against MuSK in the neuromuscular junction (NMJ). MuSK MG patients have fluctuating, fatigable skeletal muscle weakness, in particular of bulbar muscles. Severity differs greatly between patients, in spite of comparable autoantibody levels. One explanation for inter‐patient and inter‐muscle variability in sensitivity might be variations in compensatory muscle responses. Previously, we developed a passive transfer mouse model for MuSK MG. In preliminary ex vivo experiments, we observed that muscle contraction of some mice, in particular those with milder myasthenia, had become partially insensitive to inhibition by μ‐Conotoxin‐GIIIB, a blocker of skeletal muscle NaV1.4 voltage‐gated sodium channels. We hypothesised that changes in NaV channel expression profile, possibly co‐expression of (μ‐Conotoxin‐GIIIB insensitive) NaV1.5 type channels, might lower the muscle fibre's firing threshold and facilitate neuromuscular synaptic transmission. To test this hypothesis, we here performed passive transfer in immuno‐compromised mice, using ‘high’, ‘intermediate’ and ‘low’ dosing regimens of purified MuSK MG patient IgG4. We compared myasthenia levels, μ‐Conotoxin‐GIIIB resistance and muscle fibre action potential characteristics and firing thresholds. High‐ and intermediate‐dosed mice showed clear, progressive myasthenia, not seen in low‐dosed animals. However, diaphragm NMJ electrophysiology demonstrated almost equal myasthenic severities amongst all regimens. Nonetheless, low‐dosed mouse diaphragms showed a much higher degree of μ‐Conotoxin‐GIIIB resistance. This was not explained by upregulation of Scn5a (the NaV1.5 gene), lowered muscle fibre firing thresholds or histologically detectable upregulated NaV1.5 channels. It remains to be established which factors are responsible for the observed μ‐Conotoxin‐GIIIB insensitivity and whether the NaV repertoire change is compensatory beneficial or a bystander effect. Nerve stimulation‐evoked contraction of muscles from mild MuSK myasthenia gravis mice (injected with low doses patient IgG4) appeared partly insensitive to μ‑Conotoxin‐GIIIB. This blocker of NaV1.4 voltage‐gated sodium channels normally completely eliminates muscle contraction. We studied neuromuscular transmission and possible compensatory expression of NaV1.5 (cardiac‐type) channels but showed this was not the case. Which other Na channel types or related factors are involved remains to be seen.</abstract><cop>France</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38650308</pmid><doi>10.1111/ejn.16347</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0002-8427-9090</orcidid><orcidid>https://orcid.org/0009-0008-1568-5942</orcidid><orcidid>https://orcid.org/0000-0003-2538-180X</orcidid><orcidid>https://orcid.org/0000-0003-2959-559X</orcidid><orcidid>https://orcid.org/0000-0002-6082-5042</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0953-816X
ispartof The European journal of neuroscience, 2024-06, Vol.59 (12), p.3292-3308
issn 0953-816X
1460-9568
language eng
recordid cdi_proquest_miscellaneous_3045116135
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Action potential
Animals
Autoantibodies
Conotoxins - pharmacology
Diaphragm
Disease Models, Animal
Electrophysiology
Female
homeostasis
Humans
Immunization, Passive
Immunoglobulin G
Kinases
Male
Mice
Muscle contraction
Muscle, Skeletal - drug effects
Muscle, Skeletal - metabolism
Musculoskeletal system
MuSK
Myasthenia gravis
Myasthenia Gravis - immunology
Myasthenia Gravis - metabolism
Myasthenia Gravis - physiopathology
NaV channels
neuromuscular junction
Neuromuscular Junction - drug effects
Neuromuscular Junction - metabolism
Neuromuscular junctions
passive transfer
Receptor Protein-Tyrosine Kinases - metabolism
Receptors, Cholinergic - immunology
Receptors, Cholinergic - metabolism
Skeletal muscle
Sodium channels (voltage-gated)
Synaptic transmission
Voltage-Gated Sodium Channels - metabolism
title Change of voltage‐gated sodium channel repertoire in skeletal muscle of a MuSK myasthenia gravis mouse model
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T08%3A09%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Change%20of%20voltage%E2%80%90gated%20sodium%20channel%20repertoire%20in%20skeletal%20muscle%20of%20a%20MuSK%20myasthenia%20gravis%20mouse%20model&rft.jtitle=The%20European%20journal%20of%20neuroscience&rft.au=Butenko,%20Olena&rft.date=2024-06&rft.volume=59&rft.issue=12&rft.spage=3292&rft.epage=3308&rft.pages=3292-3308&rft.issn=0953-816X&rft.eissn=1460-9568&rft_id=info:doi/10.1111/ejn.16347&rft_dat=%3Cproquest_cross%3E3045116135%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3067756080&rft_id=info:pmid/38650308&rfr_iscdi=true